Acalabrutinib plus venetoclax for high-risk CLL with infection risk
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether acalabrutinib plus venetoclax can control newly diagnosed chronic lymphocytic leukemia (CLL) in people who are at higher risk of infections or who likely need treatment soon. It aims to see if this combination can improve disease control while keeping patients safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with CLL within the last year
- Your CLL risk and/or treatment needs suggest treatment is likely within about 2 years
- You have not had any prior CLL treatment (no chemotherapy, targeted medicines, or similar drugs)
- You are 18 or older and can sign consent and follow study visits and pills
- Your blood counts, liver, and kidney function meet specific lab thresholds
- You must not have active, uncontrolled infections and must pass hepatitis B and C blood tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with CLL or SLL whose cancer returned after first treatment with a similar type of therapy. The goal is to see if this approach works well with a fixed treatment duration.
This trial tests whether acalabrutinib and venetoclax (with or without early obinutuzumab) can control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is mainly for people whose disease is high-risk, has come back, or did not respond to earlier treatment.
This Phase 2 trial studies whether combining acalabrutinib and venetoclax can shrink or control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or did not respond to prior treatment. It may help by attacking the cancer using two different medicines together.
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
This trial tests whether adding acalabrutinib to obinutuzumab plus venetoclax works better than the standard combo (obinutuzumab plus venetoclax) for people with untreated, high-risk CLL. It’s designed to see if the stronger mix can improve control of the leukemia with an acceptable safety profile.
This Phase 2 study tests venetoclax plus obinutuzumab, and whether adding acalabrutinib (or not) improves outcomes for people with relapsed or refractory CLL/SLL. It aims to see which combination works best and is safe for patients whose leukemia has returned or not responded.
Hear when a new CLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.